Enterprise Value

4.795B

Cash

827M

Avg Qtr Burn

-80.12M

Short % of Float

10.72%

Insider Ownership

17.56%

Institutional Own.

88.81%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tavapadon Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Tavapadon (adjunct with L-Dopa) Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

Emraclidine (CVL-231) Details
Brain disease, Schizophrenia

Phase 2

Data readout

Darigabat Details
Social Anxiety Disorder

Phase 2

Initiation

CVL-354 Details
Major depressive disorder

Phase 1

Data readout